Enzyme inhibition and induction in liver disease.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Current Clinical Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/157488408783329896PMID 18690879
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Determinants of Drug Disposition in Patients with Cirrhosis

  2007cited by this paper
• Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis

  2006cited by this paper
• The expanding cosmos of nuclear receptor coactivators.

  2006cited by this paper
• Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2–mediated theophylline metabolism by fluvoxamine

  2006cited by this paper
• Nuclear receptors and drug disposition gene regulation.

  2005cited by this paper
• Predicting Inhibitory Drug—Drug Interactions and Evaluating Drug Interaction Reports Using Inhibition Constants

  2005cited by this paper
• METABOLISM-BASED DRUG-DRUG INTERACTIONS: WHAT DETERMINES INDIVIDUAL VARIABILITY IN CYTOCHROME P450 INDUCTION?

  2005cited by this paper
• The Hepatic Sinusoid in Aging and Cirrhosis

  2005cited by this paper
• In vitro cytochrome P450 inhibition data and the prediction of drug‐drug interactions: Qualitative relationships, quantitative predictions, and the rank‐order approach

  2005cited by this paper
• Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs

  2005cited by this paper
• Evaluation of inhibitory drug interactions during drug development: Genetic polymorphisms must be considered

  2005cited by this paper
• Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: Effects of liver function

  2004cited by this paper
• The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.

  2004cited by this paper
• The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes.

  2004cited by this paper
• Correlation between gene expression of aryl hydrocarbon receptor (AhR), hydrocarbon receptor nuclear translocator (Arnt), cytochromes P4501A1 (CYP1A1) and 1B1 (CYP1B1), and inducibility of CYP1A1 and CYP1B1 in human lymphocytes.

  2003cited by this paper
• Origins of individual variability in P4501A induction.

  2003cited by this paper
• Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications.

  2003cited by this paper
• Human Organic Anion Transporting Polypeptide-C (SLC21A6) Is a Major Determinant of Rifampin-Mediated Pregnane X Receptor Activation

  2003cited by this paper
• Prediction of human drug metabolizing enzyme induction.

  2003cited by this paper
• Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.

  2003cited by this paper
• Cationic drug pharmacokinetics in diseased livers determined by fibrosis index, hepatic protein content, microsomal activity, and nature of drug.

  2002cited by this paper
• Hepatic cytochrome P450 regulation in disease states.

  2001cited by this paper
• Induction of cytochromes P450.

  2001cited by this paper
• Induction of Drug Metabolising Enzymes

  2000cited by this paper
• Enzyme induction in the elderly: Effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone

  2000cited by this paper
• Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes.

  2000cited by this paper
• Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans.

  2000cited by this paper
• Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (review).

  1999cited by this paper
• Comparative effects of oxygen supplementation on theophylline and acetaminophen clearance in human cirrhosis.

  1999cited by this paper
• Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction.

  1998cited by this paper
• Inhibition and Induction of Cytochrome P450 and the Clinical Implications

  1998cited by this paper
• Drug elimination in chronic liver diseases.

  1997cited by this paper
• P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.

  1996cited by this paper
• Oxygen supplementation restores theophylline clearance to normal in cirrhotic rats.

  1995cited by this paper
• Genetic analysis of the S‐mephenytoin polymorphism in a chinese population

  1995cited by this paper
• Clinical Pharmacokinetic and Pharmacodynamic Considerations in Patients with Liver Disease

  1995cited by this paper
• Clearance by the liver in cirrhosis. I. Relationship between propranolol metabolism in vitro and its extraction by the perfused liver in the rat

  1993cited by this paper
• Clearance by the liver in cirrhosis. II. Characterization of propranolol uptake with the multiple‐indicator dilution technique

  1993cited by this paper
• Antipyrine clearance and response to interferon treatment in patients with chronic active hepatitis C

  1993cited by this paper
• Direct evidence for the intact hepatocyte theory in patients with liver cirrhosis.

  1992cited by this paper
• Clinical Pharmacokinetics in Patients with Liver Disease

  1991cited by this paper
• Pharmacokinetics of famotidine after intravenous administration in liver disease.

  1991cited by this paper
• Unimpaired induction of drug-metabolizing enzymes in hepatocytes isolated from rats with micronodular cirrhosis.

  1991cited by this paper
• Drug-Related Problems: Their Structure and Function

  1990cited by this paper
• Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4

  1989cited by this paper
• Drug metabolism in liver disease.

  1989cited by this paper
• Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis

  1988cited by this paper
• The liver sieve: Considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of disse

  1985cited by this paper
• Microsomal protein synthesis and induction of cytochrome P-450 in cirrhotic rat liver.

  1984cited by this paper
• Major drug interactions: effect of liver disease, alcohol, and malnutrition.

  1982cited by this paper
• Spironolactone and enzyme induction in patients with alcoholic cirrhosis.

  1980cited by this paper
• Decreased hepatic microsomal reserve in patients with cirrhosis. Studies using aminopyrine as model drug.

  1979cited by this paper
• Enhancement of hepatic drug metabolism by glutethimide in patients with liver disease

  1979cited by this paper
• Drug metabolism in liver disease: Activity of hepatic microsomal metabolizing enzymes

  1979cited by this paper
• Theophylline disposition in patients with hepatic cirrhosis.

  1977cited by this paper
• Aminopyrine breath test in alcoholic liver disease and in patients on enzyme-inducing drugs.

  1977cited by this paper
• Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance

  1977cited by this paper
• Transection of the oesophagus for bleeding oesophageal varices

  1973cited by this paper
• Determinants of serum antipyrine half-lives in patients with liver disease

  1973cited by this paper
• Phenobarbital-induced changes in NADPH-cytochrome c reductase and smooth endoplasmic reticulum in human liver.

  1972cited by this paper
• Effect of rifampicin on liver function in man

  1972cited by this paper
• The effect of cirrhosis of the liver on microsomal detoxications and cytochrome P-450.

  1969cited by this paper
• Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy.

  1968cited by this paper

• Comprehensive Toxicological Profiling of Costus pictus D. Don Methanolic Leaf Extract using In-vitro and In-vivo Model.

  2026cites this paper
• Artificial intelligence to predict inhibitors of drug-metabolizing enzymes and transporters for safer drug design

  2025cites this paper
• Identification of Putative Toxicophores in Annona muricata Phytochemical and their Hepatotoxic Potential

  2024cites this paper
• The Role of Sex in Acute and Chronic Liver Damage

  2022cites this paper
• The Metabolic Activation of Sofosbuvir Is Impaired in an Experimental Model of NAFLD

  2022cites this paper
• The Nuclear Receptor PXR in Chronic Liver Disease

  2021cites this paper
• Sources of Interindividual Variability.

  2021cites this paper
• Hepatotoxicity of decabromodiphenyl ethane (DBDPE) and decabromodiphenyl ether (BDE-209) in 28-day exposed Sprague-Dawley rats.

  2019cites this paper
• Pregnane X receptor and constitutive androstane receptor modulate differently CYP3A-mediated metabolism in early- and late-stage cholestasis

  2017cites this paper
• Pharmacokinetic drug interactions in liver disease: An update.

  2016cites this paper
• Pharmacokinetics of Antidepressants in Patients with Hepatic Impairment

  2014cites this paper
• Differential Effect of Liver Cirrhosis on the Pregnane X Receptor–Mediated Induction of CYP3A1 and 3A2 in the Rat

  2014cites this paper
• Sources of interindividual variability.

  2014cites this paper
• Effetto della disfunzione epatica sull’induzione enzimatica: valutazione dell’inducibilità dei CYP1A e CYP3A in ratti con cirrosi sperimentalmente indotta

  2014cites this paper
• Discussion of “Attitude of Physi -cians Towards Automatic Alerting in Computerized Physician Order Entry Systems”

  2013cites this paper
• Severe Liver Cirrhosis Markedly Reduces AhR-Mediated Induction of Cytochrome P450 in Rats by Decreasing the Transcription of Target Genes

  2013cites this paper
• Tethered spheroids as an in vitro hepatocyte model for drug safety screening.

  2012cites this paper
• Attitude of Physicians Towards Automatic Alerting in Computerized Physician Order Entry Systems

  2012cites this paper
• Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Mild Hepatic Impairment

  2011cites this paper
• The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update

  2010cites this paper
• Kaposi sarcoma is the most common cancer diagnosed in HIV-infected persons.

  2009cites this paper
• Irreversible CYP3A Inhibition Accompanied by Plasma Protein–Binding Displacement: A Comparative Analysis in Subjects With Normal and Impaired Liver Function

  2009cites this paper